NOVEN PHARMACEUTICALS INC Business Operations Contracts & Agreements
8 Contracts & Agreements
- Administration Agreements (4 contracts)
- Sales Agreements (1)
- Supply Agreements (2)
- Termination Agreements (1)
- Daytrana, the first and only transdermal patch approved by the United States Food & Drug Administration (FDA) for the treatment of ADHD (Filed With SEC on March 13, 2009)
- Daytrana, the first and only transdermal patch approved by the United States Food & Drug Administration (FDA) for the treatment of ADHD (Filed With SEC on March 13, 2009)
- Daytrana, the first and only transdermal patch approved by the United States Food & Drug Administration (FDA) for the treatment of ADHD (Filed With SEC on March 13, 2009)
- Daytrana, the first and only transdermal patch approved by the United States Food & Drug Administration (FDA) for the treatment of ADHD (Filed With SEC on March 13, 2009)
- EX-10.48 Manufacturing and Supply Agreement (Filed With SEC on April 1, 2008)
- EX-10.6 Manufacturing and Supply Agreement (Filed With SEC on November 9, 2007)
- TERMINATION AGREEMENT (Filed With SEC on March 15, 2006)
- 2006 Base Salaries for Executive Officers Name and Title Salary Robert C. Strauss President & Chief Executive Officer $ 587,741 Eduardo G. Abrao, M.D. Vice President & Chief... (Filed With SEC on December 8, 2005)
